A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A Phase 1, double-blinded, placebo-controlled study to assess the safety, tolerability, and
pharmacokinetics of BSG005 following single and multiple ascending doses in healthy male
subjects. The study will include a single ascending dose part and a multiple ascending dose
part